The trusted source for
healthcare information and
Abbott recalls low-calcium/ vitamin D-free infant formula
Abbott has announced a voluntary worldwide recall of two lots of Calcilo XD® Low-Calcium/Vitamin D-Free Infant Formula with Iron powder in 14.1-ounce cans (400g). Only the 14.1-ounce (400g) cans are involved in this action. Calcilo XD® is a low-calcium and vitamin D-free infant formula that is specifically designed for the nutrition support of infants and children with hypercalcemia. It is only available by special order.
Abbott is voluntarily recalling two lots of product because small amounts of air may have entered the can, resulting in product oxidation. A common sign of oxidation is an off aroma. Consumption of highly oxidized foods can cause gastrointestinal symptoms such as nausea, vomiting, and diarrhea. If parents have questions or concerns they should contact a health care professional.
The problem is isolated to the lots of Calcilo XD Powder in 14.1-ounce (400g) cans, with stock code number 00378 and with lot numbers 39973RB or 47239RB6 printed on the bottom of the cans. No other Calcilo XD powdered infant formulas are affected.
The two lots were distributed in the United States, Canada, Malaysia, Korea, and Bahrain, between 06/06/06 and 04/17/08. Consumers who purchased Calcilo XD® Low-Calcium/Vitamin D-Free Infant Formula with Iron powder from either of the two lots mentioned above should contact Abbott Nutrition at (800) 638-6493.
Abbott is working with its distribution partners and the US FDA to execute this recall.
Obese adults no more likely to use CAM, study says
Although obesity is associated with higher health care costs, obese individuals are not more likely to turn to complementary and alternative medicine (CAM) than people of normal weight, says a study published May 1 on the website for the journal Obesity.
Researchers at Osher Research Center and Beth Israel Deaconess Medical Center at Harvard Medical School in Boston, MA, wanted to examine the relationship between obesity and the use of CAM. To do this, they analyzed data on CAM use from the 2002 National Health Interview Survey (NHIS) Alternative Medicine Supplement. They compared the use of CAM overall, within the past 12 months, between normal weight (BMI from 18 to < 25), overweight (from 25 to < 30), mildly obese (from 30 to < 35), moderately obese (from 35 to < 40), and extremely obese (> 40) adults.
For the primary analysis, the researchers' multivariable model was adjusted for sociodemographic factors, insurance status, medical conditions, and health behaviors. The researchers performed additional analyses to explore the association of BMI and the use of seven CAM modalities.
The analyses showed that adults with obesity have lower prevalence of yoga therapy use, and similar prevalence of use of several CAM modalities, including relaxation techniques, natural herbs, massage, chiropractic medicine, tai chi, and acupuncture, compared to normal-weight individuals. After adjustment for sociodemographic factors, insurance status, medical conditions, and health behaviors, adults with obesity were generally less likely to use most individual CAM modalities, although the differences often were modest, the researchers say. They concluded that additional research was needed to improve the understanding of CAM use by obese adults.
NCCAM names director of the Division of Extramural Activities
Martin H. Goldrosen, PhD, has been appointed director of the Division of Extramural Activities (DEA) at the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health (NIH).
The division, through its Office of Scientific Review, coordinates the receipt, referral, and scientific review of grants, cooperative agreements, and research contracts. Its Office of Grants Management oversees the processing of grant, cooperative agreement, and contract awards. The division also coordinates meetings and directs committee management activities for the National Advisory Council for Complementary and Alternative Medicine.
Goldrosen began his NIH career in 1991 as a health scientist administrator within the Grants Review Branch of the Division of Extramural Affairs at the National Cancer Institute. Prior to joining NIH, he was a cancer research scientist at the Roswell Park Cancer Institute in New York. Concurrently, Goldrosen was a Research Professor of Experimental Pathology at the State University of New York in Buffalo.